Literature DB >> 22023785

Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain.

Olga Chernoloz1, Mostafa El Mansari, Pierre Blier.   

Abstract

BACKGROUND: Long-term administration of the dopamine (DA) D2-like (D3/2) receptor agonist pramipexole (PPX) has been previously found to desensitize D2 autoreceptors, thereby allowing a normalization of the firing of DA neurons and serotonin (5-HT)1A autoreceptors, permitting an enhancement of the spontaneous firing of 5-HT neurons. We hypothesized that PPX would increase overall DA and 5-HT neurotransmission in the forebrain as a result of these changes at the presynaptic level.
METHODS: Osmotic minipumps were implanted subcutaneously in male Sprague-Dawley rats, delivering PPX at a dose of 1 mg/kg/d for 14 days. The in vivo electrophysiologic microiontophoretic experiments were carried out in anesthetized rats.
RESULTS: The sensitivity of postsynaptic D2 receptors in the prefrontal cortex (PFC) remained unaltered following PPX administration, as indicated by the unchanged responsiveness to the microiontophoretic application of DA. Their tonic activation was, however, significantly increased by 104% compared with the control level. The sensitivity of postsynaptic 5-HT1A receptors was not altered, as indicated by the unchanged responsiveness to the microiontophoretic application of 5-HT. Similar to other antidepressant treatments, long-term PPX administration enhanced the tonic activation of 5-HT1A receptors on CA3 pyramidal neurons by 142% compared with the control level. LIMITATIONS: The assessment of DA and 5-HT neuronal tone was restricted to the PFC and the hippocampus, respectively.
CONCLUSION: Chronic PPX administration led to a net enhancement in DA and 5-HT neurotransmission, as indicated by the increased tonic activation of postsynaptic D2 and 5-HT1A receptors in forebrain structures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22023785      PMCID: PMC3297071          DOI: 10.1503/jpn.110038

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  65 in total

Review 1.  Autoregulation of serotonin neurons: role in antidepressant drug action.

Authors:  G Piñeyro; P Blier
Journal:  Pharmacol Rev       Date:  1999-09       Impact factor: 25.468

Review 2.  Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.

Authors:  J P Bennett; M F Piercey
Journal:  J Neurol Sci       Date:  1999-02-01       Impact factor: 3.181

3.  Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.

Authors:  Mauricette Brocco; Anne Dekeyne; Mariusz Papp; Mark J Millan
Journal:  Behav Pharmacol       Date:  2006-11       Impact factor: 2.293

4.  In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals.

Authors:  Y Chaput; P Blier; C de Montigny
Journal:  J Neurosci       Date:  1986-10       Impact factor: 6.167

5.  Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness.

Authors:  H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox
Journal:  Am J Psychiatry       Date:  1999-05       Impact factor: 18.112

6.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.

Authors:  H S Mayberg; S K Brannan; J L Tekell; J A Silva; R K Mahurin; S McGinnis; P A Jerabek
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

7.  Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex.

Authors:  Jason J Radley; Anne B Rocher; Alfredo Rodriguez; Douglas B Ehlenberger; Mark Dammann; Bruce S McEwen; John H Morrison; Susan L Wearne; Patrick R Hof
Journal:  J Comp Neurol       Date:  2008-03-01       Impact factor: 3.215

8.  Antidepressant-like effects of dopamine agonists in an animal model of depression.

Authors:  R Muscat; M Papp; P Willner
Journal:  Biol Psychiatry       Date:  1992-05-01       Impact factor: 13.382

Review 9.  Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

Authors:  M F Piercey
Journal:  Clin Neuropharmacol       Date:  1998 May-Jun       Impact factor: 1.592

10.  Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex.

Authors:  A M Thierry; C Le Douarin; J Penit; A Ferron; J Glowinski
Journal:  Brain Res Bull       Date:  1986-02       Impact factor: 4.077

View more
  11 in total

1.  The influence of bromocryptine treatment on activity of the adenylyl cyclase system in the brain of rats with type 2 diabetes mellitus induced by high-fat diet.

Authors:  A O Shpakov; K V Derkach; O V Chistyakova; V M Bondareva
Journal:  Dokl Biochem Biophys       Date:  2015-01-06       Impact factor: 0.788

2.  Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice.

Authors:  Patrick S Johnson; Jeffrey S Stein; Rochelle R Smits; Gregory J Madden
Journal:  J Exp Anal Behav       Date:  2013-02-22       Impact factor: 2.468

Review 3.  Impulse control disorders in Parkinson's disease.

Authors:  Ana Marques; Franck Durif; Pierre-Olivier Fernagut
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

4.  Increased motor impulsivity in a rat gambling task during chronic ropinirole treatment: potentiation by win-paired audiovisual cues.

Authors:  Melanie Tremblay; Michael M Barrus; Paul J Cocker; Christelle Baunez; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2019-01-31       Impact factor: 4.530

Review 5.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 6.  The benefits of pramipexole selection in the treatment of Parkinson's disease.

Authors:  Mine Silindir; A Yekta Ozer
Journal:  Neurol Sci       Date:  2014-07-20       Impact factor: 3.307

7.  Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans.

Authors:  Thomas F Newton; Colin N Haile; James J Mahoney; Ravi Shah; Christopher D Verrico; Richard De La Garza; Thomas R Kosten
Journal:  Psychiatry Res       Date:  2015-07-29       Impact factor: 3.222

8.  Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.

Authors:  Franklin R Schneier; Mark Slifstein; Alexis E Whitton; Diego A Pizzagalli; Jenna Reinen; Patrick J McGrath; Dan V Iosifescu; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2018-05-25       Impact factor: 13.382

9.  Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.

Authors:  Franck Chenu; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

10.  Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease.

Authors:  Andrew D Lawrence; David J Brooks; Alan L Whone
Journal:  Front Psychol       Date:  2013-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.